A year ago, I made a video about vitamin K2. I called the heart evidence intriguing — but unproven. I said we needed a bigger, cleaner trial before anyone should get excited.
Well, that trial just landed. And it did exactly what was hoped: the vitamin K2 group built up less calcium in their arteries than the placebo group [1].
So you'd think I'd be telling you it's a win. I'm not. Reading it carefully made me more cautious, not less. Let me explain why.
Table of Contents
- First, let's clear up the biggest myth
- The trial that got stronger
- A number is not an outcome
- The calcium paradox
- Bone — the more reasonable case
- The catch nobody mentions
- A sensible dose, and one safety point
- References
First, let's clear up the biggest myth
Before we get to the trial, let's clear up one thing you've almost certainly been told: that you have to take K2 with vitamin D and magnesium, or it doesn't work, or the calcium ends up in your arteries.
That's overblown. Get good amounts of vitamin D and magnesium — the same as every other vitamin and mineral — and you're fine. The trial I'm about to show you, the strongest one for K2 and your heart, used K2 on its own. The point isn't that magnesium and vitamin D don't matter. It's that you don't need to megadose them. With that out of the way, here's the trial — and then I'll explain my concerns.
The trial that got stronger
Researchers gave 360 micrograms of K2, on its own, every day for two years, to people who already had some calcium building up in their coronary arteries [1]. That's an important point: these participants already had diseased blood vessels.
Over those two years, the calcium score went up in everyone — but it climbed less in the K2 group. In plain numbers: the calcium score rose about 36% on K2 versus 48% on placebo. And the actual mass of calcium — a more reliable way to measure it — rose 7 milligrams on K2 versus 12 on placebo [2].
That matters more than it sounds. A calcium score can be a bit jumpy — it can wobble depending on exactly how the scan picks up dense, bright flecks. So the fact that the calcium mass moved in the same direction as the score is reassuring. It tells you this probably isn't a quirk of one measurement method. Both pointed the same way.
They also checked a blood marker that tells you whether the K2 was actually switching on the system it's supposed to switch on inside the body — and it moved the right way too. So the mechanism fired. The K2 got in, it did its job, and the calcium climbed more slowly. Three separate signals, all lined up. As a piece of biology, it's clean.
And this is a real step up from where we were a year ago. The trial I covered back then was Danish — and it was null overall. It only showed a benefit in the people who already had the most calcium to begin with [3]. This new one is cleaner: pure K2, both men and women, a real result across the whole group, not just one slice of it.
So — settled, take K2 for your heart? No. And the honest catch comes in the same breath as the good news. The authors themselves call the effect "modest." And there's a number inside the trial that matters. They looked at the people whose calcium was racing ahead — the fast progressors — and asked whether K2 cut that group down. It didn't. The share of fast progressors was basically the same in both groups [1].
And there's one more thing. This positive trial doesn't sit on its own. It sits in a small crowd of trials where K2 did nothing at all. In people with type-2 diabetes — nothing [4]. In people with kidney disease — nothing, including one trial at a 90-microgram dose [5][6]. So read it all together and a pattern shows up: K2 seems to slow calcium build-up for people who already have calcium quietly building up. It is not a "take it and stay clean forever" pill. Which is interesting. But even taking the best possible reading of it — even if every bit of that benefit is real — there's a much bigger problem waiting underneath it.
A number is not an outcome
Slowing a calcium score is not the same as preventing a heart attack. A higher calcium score does track with higher risk — but it is a measurement on a scan, not an event in your life. And no K2 trial has ever shown the thing that actually matters: fewer heart attacks, fewer deaths.
In fact, the one trial that did look at hard outcomes — real heart attacks and real deaths, in dialysis patients — found no difference at all [7]. Now, that trial was small, and it was in a very specific group of patients on dialysis, so it doesn't slam the door. But it's the only hard-outcome trial we've got, and it came back empty.
But surely — less calcium has to be better than more, right? Less gunk in the artery, less danger. That feels obvious. And that's exactly where this story gets strange.
The calcium paradox
Picture plaque in an artery wall. It's a soft, inflamed, greasy little pocket — and that's the dangerous kind. The danger isn't really the calcium. The danger is that pocket bursting open and triggering a clot.
Now, what does the body do to a wound it can't fully heal? It walls it off. It lays down hard calcium over the top — like a shell, like a scar, like a scab that's gone solid. That hard, dense calcium isn't the bomb. It's the casing around the bomb. It's holding the dangerous stuff shut. The body deposits calcium to try to stabilise the plaque.
Which makes the unsettling question even sharper. When K2 slows the calcium down — is it slowing plaque stabilisation? Is it leaving vulnerable plaque to rupture? A scan that just gives you one total number can't tell those two apart. It counts the calcium. It doesn't ask whose side it's on. Which is why we need the hard-outcome data — what happens to heart attack rates, not just what happens on a scan.
This isn't me being clever for the sake of it. There's a real, well-known example that turns the obvious intuition completely upside down: statins. Statins are one of the best-proven medicines we have for cutting heart attacks and deaths. And here's the strange part: statins actually increase the calcium in your arteries. They harden the plaque. They turn that soft dangerous pocket into solid, stable scar tissue — and people do better [8].
Sit with that for a second. A drug that adds calcium to your arteries saves lives. So "more calcium on the scan" can be the good direction in the right context. Which means moving calcium the other way — slowing it down — could just as easily be neutral, helpful, or quietly harmful. We genuinely do not know which.
And I want to be really careful here, because this is the part that gets twisted into a scare story, and it shouldn't be. K2 is not ripping calcium out of the stable scar tissue you've already built. It's slowing down new calcium forming in plaques that are still developing. Those might be two completely different things. Slowing the new stuff might be totally fine. It might even be good. But it might not.
And the new trial can't answer it — because it didn't look. It measured the calcium. It did not measure the soft, dangerous non-calcified plaque itself. It didn't measure how much of it there was, or whether it got more stable or less [1].
So the headline — "K2 slows artery calcium" — is true. And the question that actually decides whether you should care — "is that good for your heart?" — is wide open. That's not a dodge. That's just where the science honestly is right now. To me, right now, there isn't compelling evidence to take vitamin K2 for heart health. But there's a whole other half of the K2 story: bone.
Bone — the more reasonable case
If you're going to take K2 for anything, bone is where the evidence is most reasonable — more reasonable, honestly, than the heart. There's some decent trial evidence that K2 helps slow the loss of bone density as you age. The best single trial used 180 micrograms a day over three years, and it modestly slowed the decline in bone density at the spine and the hip [9].
But here's the line that's the whole game with bone. Improving bone density is not the same as preventing a fracture. Density is a number on a scan. A fracture is the thing that actually breaks your hip and changes your life. And when you look specifically at fractures, K2 hasn't been shown to reduce them [10].
So the honest position on bone is the same shape as the heart: some evidence for density, none so far for fractures. It's the most reasonable reason to take K2 — and it still comes with a caveat. I'd much rather give you the full picture, and be clear about where the evidence is lacking. So if you've heard all that and you still decide it's worth a try — fair enough. Then two practical things genuinely matter. And the first one almost nobody talks about.
The catch nobody mentions — K2 falls apart unless it's protected
A lot of the K2 sitting on shelves right now isn't really there by the time you swallow it. The form used in all these trials is called MK-7. And MK-7 is fragile. Over time it slowly flips from its active form into an inactive one — same molecule, wrong shape, doesn't work. And that breakdown speeds up when you pack the K2 into the same pill as minerals like calcium and magnesium.
This isn't theoretical. When an independent lab actually tested popular K2 products, it caught some carrying only a fraction of what was on the label. One well-known product had barely a third of its claimed K2 [2].
The fix on the manufacturing side is to use a protected, encapsulated form — one that's coated so it survives sitting next to those minerals without breaking down. And even if a label says the vitamin K2 is in an encapsulated form, it's best to verify that claim by checking third-party testing websites such as consumerlab.com or labdoor.com. Once you've sorted out whether the K2 is actually in the supplement you're buying, there's the dose — plus one safety point.
A sensible dose, and one safety point you can't skip
Let's start with how much. The numbers from the trials sound big — 180, 360, even 720 micrograms. But there's no recognised recommended daily requirement for vitamin K2 (for vitamin K1 it's 120 micrograms). So what's a sensible K2 supplement dose? Difficult to say, because again we lack the required data.
The doses in the studies we've looked at range from 180 to 360 micrograms. No upper safe limit has ever been set for K2, and the longest trials only ran three years. So nobody actually knows what taking 360 micrograms a day for, say, twenty years does. Given that, a more conservative strategy would be to take something like 90 micrograms a day — a dose that doesn't bet your next two decades on the high experimental amounts before anyone's checked they're safe long-term. To be clear about what that 90 is and isn't: it's a cautious, adequacy-based choice. It is not "the dose proven to slow your calcium." The trials that moved the scan used more. If someone tells you 90 micrograms is the clinically proven heart dose, that's not what the evidence says.
Now the safety point. If you're on warfarin — the old blood thinner, the one where you get regular blood tests — you should be extremely cautious with vitamin K2. Vitamin K works directly against warfarin, and MK-7 does it even at tiny doses, because it hangs around in your body for days. Some experts say warfarin patients should avoid it entirely [2].
One important reassurance on that: this is specifically a warfarin problem. Aspirin, and the newer blood thinners — apixaban, dabigatran, and rivaroxaban — are not affected. It's warfarin where vitamin K is the issue.
So where does that leave us? Overall, this new trial is tentatively positive. There's a theoretical possibility that vitamin K2 might even worsen heart attack rates, and what we really need now is a trial that looks at hard outcomes like heart attacks and strokes. Until then, be careful with dosages, and look for third-party tests of supplement label claims. The evidence got stronger — and I got more careful. Those two things aren't a contradiction. "Slows a calcium score" and "prevents a heart attack" are two different sentences, and anyone selling you the second one is well out ahead of the data.
References
1. https://doi.org/10.1001/jamacardio.2026.1279
2. https://www.consumerlab.com/reviews/vitamin-k-supplements-review/vitamin-k/
3. https://doi.org/10.1016/j.jacadv.2023.100643
4. https://doi.org/10.1093/ajcn/nqy373
5. https://doi.org/10.1681/ASN.2020020225
6. https://doi.org/10.20452/pamw.3041
7. https://pubmed.ncbi.nlm.nih.gov/37705910/
8. https://doi.org/10.1016/j.jacc.2015.01.036
